Press Release

Enteris BioPharma
to participate in DCAT Week, 2022

Boonton, NJ – March 03, 2022 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly- owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that the company will participate in DCAT® Week 2022 being held March 21-24, 2022 in New York City.


    EnterisBioPharma is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

    You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

    By clicking submit below, you consent to allow EnterisBioPharma to store and process the personal information submitted above to provide you the content requested.

    Meet Enteris Biopharma at DCAT Week 2022

    Fill out our contact form below if you’d like to arrange a time to discuss how we can help with your next drug product development.